Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS

Summary

A multidose open-label study with autologous Mesenchymal Stromal Stem Cells Secreting Neurotrophic Factors (MSC-NTF cells) involving 20 participants with progressive MS at multiple investigational study sites.

Timeline

Start

2019-03-13

Primary completion

2021-03-11

Completion

2021-03-30

Outcome

Met primary endpoint

release “The trial achieved the primary endpoint of safety and demonstrated clinically meaningful improvements in multiple endpoints.” brainstorm-cell.com ↗

release “NurOwn (autologous MSC-NTF cells) in participants with progressive MS. The study achieved the primary endpoint of safety and tolerability.” brainstorm-cell.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NurOwn	Cell therapy	—	Intrathecal

Indications